Dr Reddy's Laboratories has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, DRL will launch Kyprolis (carfilzomib), Blincyto (blinatumomab and Repatha (evolocumab) in India.
Meanwhile, DRL is planning to expand its presence in western Europe like France, Italy and Spain with new products in the coming years. The company is looking out good opportunities for acquisition and mergers. Its revenue from North America worked out to 44 per cent of its total revenues and that from India contributed around 15 per cent. Russian market remained as second largest contributor in its total revenue. However, depreciation of Russian currency against US dollar put pressure on Russian sales.
DRL has changed its brand which is based on a heart which represents its empathy for patients and partners. It embodies its sensitivity to patients problems, and its relentless search for solutions that bring good health to them. The circles on the right represent the dynamism that DRL bring to its work – always striving to be the first to bring good health to the world. The company choose purple as its corporate colour, which is signifies the balance between the stimulating red and the calming blue.